RS62341B1 - Fuzioni proteini za lečenje metaboličkih poremećaja - Google Patents

Fuzioni proteini za lečenje metaboličkih poremećaja

Info

Publication number
RS62341B1
RS62341B1 RS20211120A RSP20211120A RS62341B1 RS 62341 B1 RS62341 B1 RS 62341B1 RS 20211120 A RS20211120 A RS 20211120A RS P20211120 A RSP20211120 A RS P20211120A RS 62341 B1 RS62341 B1 RS 62341B1
Authority
RS
Serbia
Prior art keywords
fusion proteins
metabolic disorders
treating metabolic
treating
disorders
Prior art date
Application number
RS20211120A
Other languages
English (en)
Serbian (sr)
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS62341B1 publication Critical patent/RS62341B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
RS20211120A 2011-09-26 2012-09-26 Fuzioni proteini za lečenje metaboličkih poremećaja RS62341B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
EP17201957.2A EP3321276B1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders

Publications (1)

Publication Number Publication Date
RS62341B1 true RS62341B1 (sr) 2021-10-29

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20181146A RS57868B1 (sr) 2011-09-26 2012-09-26 Fuzioni proteini za lečenje metaboličkih poremećaja
RS20211120A RS62341B1 (sr) 2011-09-26 2012-09-26 Fuzioni proteini za lečenje metaboličkih poremećaja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20181146A RS57868B1 (sr) 2011-09-26 2012-09-26 Fuzioni proteini za lečenje metaboličkih poremećaja

Country Status (41)

Country Link
US (6) US9006400B2 (en:Method)
EP (2) EP3321276B1 (en:Method)
JP (4) JP6186361B2 (en:Method)
KR (1) KR102085605B1 (en:Method)
CN (2) CN103945871B (en:Method)
AP (1) AP2014007543A0 (en:Method)
AR (2) AR088044A1 (en:Method)
AU (1) AU2012316052A1 (en:Method)
BR (1) BR112014007069B1 (en:Method)
CA (1) CA2849464C (en:Method)
CL (2) CL2014000736A1 (en:Method)
CO (1) CO6920257A2 (en:Method)
CR (1) CR20140140A (en:Method)
CU (2) CU24314B1 (en:Method)
CY (2) CY1120928T1 (en:Method)
DK (2) DK2760475T3 (en:Method)
EA (1) EA039633B1 (en:Method)
ES (2) ES2895080T3 (en:Method)
GT (1) GT201400055A (en:Method)
HR (2) HRP20181558T1 (en:Method)
HU (2) HUE039857T2 (en:Method)
IL (1) IL231533B (en:Method)
IN (1) IN2014DN02043A (en:Method)
JO (1) JO3476B1 (en:Method)
LT (2) LT3321276T (en:Method)
MA (1) MA35437B1 (en:Method)
MX (1) MX350273B (en:Method)
MY (1) MY166059A (en:Method)
PE (2) PE20181159A1 (en:Method)
PL (2) PL2760475T3 (en:Method)
PT (2) PT2760475T (en:Method)
RS (2) RS57868B1 (en:Method)
SG (2) SG11201400538QA (en:Method)
SI (2) SI3321276T1 (en:Method)
SM (1) SMT202100595T1 (en:Method)
TN (1) TN2014000109A1 (en:Method)
TW (1) TWI593708B (en:Method)
UA (1) UA113856C2 (en:Method)
UY (2) UY34346A (en:Method)
WO (1) WO2013049247A1 (en:Method)
ZA (1) ZA201401700B (en:Method)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012528A1 (en) 2006-07-25 2008-01-31 Lipoxen Technologies Limited N-terminal polysialylation
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2726511B1 (en) 2011-07-01 2019-08-07 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PL2938740T3 (pl) 2012-12-27 2022-07-11 Ngm Biopharmaceuticals, Inc. Chimeryczne peptydy fgf19 do zastosowania w leczeniu zaburzeń gospodarki kwasami żółciowymi
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX392683B (es) * 2014-10-23 2025-03-24 Ngm Biopharmaceuticals Inc Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3185706A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
BR112018073861A2 (pt) * 2016-05-20 2019-02-26 President And Fellows Of Harvard College métodos de terapia de genes para doenças e condições relacionadas com a idade
MX2018014475A (es) 2016-05-25 2019-05-23 Univ Texas Métodos y composiciones para el tratamiento de trastornos secretorios.
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759697B (zh) * 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
EP3558341A1 (en) 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
US11479591B2 (en) 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN119386162A (zh) * 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CA3164941A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023540663A (ja) * 2020-07-02 2023-09-26 サノフイ Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1232264B1 (en) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE339450T1 (de) 1999-12-23 2006-10-15 Zymogenetics Inc Verfahren zur behandlung von entzündungen
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP4477013B2 (ja) * 2003-12-10 2010-06-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
DK1751184T3 (da) * 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
PT1789442E (pt) * 2004-09-02 2009-11-11 Lilly Co Eli Muteínas do factor de crescimento de fibroblasto 21
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009308163B2 (en) 2008-10-24 2013-01-10 Novartis Ag Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
PE20120358A1 (es) * 2009-05-05 2012-04-26 Amgen Inc Mutantes fgf21 y usos de los mismos
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Also Published As

Publication number Publication date
CL2014000736A1 (es) 2014-10-03
IL231533A0 (en) 2014-04-30
AR088044A1 (es) 2014-05-07
LT2760475T (lt) 2018-10-25
KR20140069250A (ko) 2014-06-09
PL3321276T3 (pl) 2022-01-17
EP2760475B1 (en) 2018-07-04
BR112014007069B1 (pt) 2020-12-15
EP3321276A2 (en) 2018-05-16
JO3476B1 (ar) 2020-07-05
TWI593708B (zh) 2017-08-01
JP7339372B2 (ja) 2023-09-05
SG10201602339XA (en) 2016-05-30
IL231533B (en) 2018-06-28
HK1251238A1 (en) 2019-01-25
EP3321276B1 (en) 2021-07-28
DK2760475T3 (en) 2018-10-15
EA039633B1 (ru) 2022-02-18
US20160193297A1 (en) 2016-07-07
HUE055584T2 (hu) 2021-12-28
CR20140140A (es) 2014-07-15
CN107266579A (zh) 2017-10-20
RS57868B1 (sr) 2018-12-31
US20210386824A1 (en) 2021-12-16
DK3321276T3 (da) 2021-10-25
CU24206B1 (es) 2016-10-28
ZA201401700B (en) 2015-01-28
HRP20211575T1 (hr) 2022-02-04
CU20140034A7 (es) 2014-08-28
JP2018023370A (ja) 2018-02-15
US20130079500A1 (en) 2013-03-28
SG11201400538QA (en) 2014-06-27
SMT202100595T1 (it) 2022-01-10
CA2849464C (en) 2024-01-30
JP2020007314A (ja) 2020-01-16
JP6186361B2 (ja) 2017-08-23
EP2760475A1 (en) 2014-08-06
IN2014DN02043A (en:Method) 2015-05-15
US10076554B2 (en) 2018-09-18
CA2849464A1 (en) 2013-04-04
LT3321276T (lt) 2021-11-10
CN107266579B (zh) 2022-07-12
ES2689762T3 (es) 2018-11-15
PL2760475T3 (pl) 2018-11-30
CY1124697T1 (el) 2022-07-22
JP2014534172A (ja) 2014-12-18
CO6920257A2 (es) 2014-04-10
TW201326213A (zh) 2013-07-01
MY166059A (en) 2018-05-22
KR102085605B1 (ko) 2020-03-06
CU20150171A7 (es) 2016-07-29
US20180369332A1 (en) 2018-12-27
US9266935B2 (en) 2016-02-23
WO2013049247A1 (en) 2013-04-04
US9006400B2 (en) 2015-04-14
US20150166622A1 (en) 2015-06-18
TN2014000109A1 (en) 2015-07-01
UA113856C2 (xx) 2017-03-27
JP2022058546A (ja) 2022-04-12
SI2760475T1 (sl) 2018-10-30
MA35437B1 (fr) 2014-09-01
CU24314B1 (es) 2018-02-08
CL2016002215A1 (es) 2016-10-28
HUE039857T2 (hu) 2019-02-28
BR112014007069A2 (pt) 2017-03-28
NZ622998A (en) 2016-07-29
EP3321276A3 (en) 2018-06-20
US11944664B2 (en) 2024-04-02
CN103945871A (zh) 2014-07-23
PE20181159A1 (es) 2018-07-19
GT201400055A (es) 2017-09-28
MX2014003677A (es) 2014-04-30
PE20141551A1 (es) 2014-10-26
UY39119A (es) 2021-04-30
ES2895080T3 (es) 2022-02-17
MX350273B (es) 2017-08-31
AR123908A2 (es) 2023-01-25
PT2760475T (pt) 2018-10-25
UY34346A (es) 2013-04-30
AP2014007543A0 (en) 2014-03-31
US20240261372A1 (en) 2024-08-08
AU2012316052A1 (en) 2014-04-17
HRP20181558T1 (hr) 2018-11-30
SI3321276T1 (sl) 2021-11-30
PT3321276T (pt) 2021-10-27
JP6567613B2 (ja) 2019-08-28
US11129874B2 (en) 2021-09-28
EA201490695A1 (ru) 2015-10-30
CY1120928T1 (el) 2019-12-11
CN103945871B (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
IL231533A0 (en) Fusion proteins for the treatment of metabolic disorders
IL231647A0 (en) Proteins with dual activity for the treatment of metabolic disorders
IL237032A0 (en) Fusion proteins for the treatment of metabolic syndrome
PL2726099T3 (pl) Sposób leczenia zaburzeń metabolicznych
IL229254A0 (en) Therapeutic antibodies
PT2783256T (pt) Óculos terapêuticos
ZA201502595B (en) Therapeutic methods
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
ZA201308992B (en) Therapeutic antibodies
HUP1100282A2 (en) Protein factor
TH148777B (th) ฟิวชั่นโปรตีนสำหรับบำบัดความผิดปกติเกี่ยวกับเมทาบอลิซึม
GB201103169D0 (en) Protein expression
GB201107212D0 (en) Eyewear